Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    134

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,804.8714.600.19%
DAX 4024,304.4619.12-0.08%
Dow JONES (US)42,762.87443.131.05%
FTSE 1008,837.9126.870.30%
HKSE23,792.54114.43-0.48%
NASDAQ19,529.95231.511.20%
Nikkei 22537,741.61187.120.50%
NZX 50 Index12,563.4813.67-0.11%
S&P 5006,000.3661.061.03%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,385.361.260.04%

Market Movers